Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear. We generated humanized RANKL mice and treated them with d...

Full description

Bibliographic Details
Main Authors: Qiang Fu, Nancy C. Bustamante-Gomez, Humberto Reyes-Pardo, Igor Gubrij, Diana Escalona-Vargas, Jeff D. Thostenson, Michela Palmieri, Joseph J. Goellner, Intawat Nookaew, C. Lowry Barnes, Jeffrey B. Stambough, Elena Ambrogini, Charles A. O’Brien
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-09-01
Series:JCI Insight
Subjects:
Bone biology
Online Access:https://doi.org/10.1172/jci.insight.167790

Internet

https://doi.org/10.1172/jci.insight.167790

Similar Items